



Final Appraisal Recommendation

Advice No: 1014 – May 2014

**Fluticasone furoate/vilanterol (as trifenate)
(Relvar[®] Ellipta[®]▼)
92 micrograms/22 micrograms inhalation powder**

Submission by GlaxoSmithKline

Recommendation of AWMSG

Fluticasone furoate/vilanterol (as trifenate) (Relvar[®] Ellipta[®]▼) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV₁ < 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

Additional note:

- **Fluticasone furoate/vilanterol (as trifenate) (Relvar[®] Ellipta[®]▼) should be used in line with NICE Clinical Guideline on chronic obstructive pulmonary disease for the symptomatic treatment of adults.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1534), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	GlaxoSmithKline
Date of first issue	May 2014
Last reviewed	May 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1534:
fluticasone furoate/vilanterol (as trifenate) 92 micrograms/22 micrograms inhalation powder
May 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.